Cladribine

Generic Name: Cladribine

Brand Names: Litak, Mavenclad

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂ClN_₅O_₃

CAS Number: 4291-63-8

Unique Ingredient Identifier: 47M74X9YT5

Background: An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.

Indication: For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.

Associated Conditions: Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)

Clinical Trials

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Phase 2

Recruiting

Conditions: Langerhans Cell Histiocytosis

Interventions: Procedure: hematopoietic stem cell transplantation (RIC-HSCT)
Drug: Prednisone
Drug: 2-chlorodeoxyadenosine
Drug: Vinblastine
Biological: Intravenous immunoglobulin
Drug: mercaptopurine
Drug: INDOMETHACIN
Drug: Methotrexate
Drug: Cytosine Arabinoside

First Posted Date: 2014-07-31

Last Posted Date: 2023-03-23

Lead Sponsor: North American Consortium for Histiocytosis

Target Recruit Count: 1400

Registration Number: NCT02205762

Locations: 🇺🇸
Children's Medical Center Dallas, UT Southwestern, Dallas, Texas, United States
🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 35 locations

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Phase 2

Recruiting

Conditions: Hairy Cell Leukemia

Interventions: Drug: Cladribine s.c. injection, HCL treatment

First Posted Date: 2014-05-06

Last Posted Date: 2024-08-22

Lead Sponsor: University of Giessen

Target Recruit Count: 210

Registration Number: NCT02131753

Locations: 🇩🇪
Rhön-Saale-Klinik gGmbH, Bad Neustadt An Der Saale, Germany
🇩🇪
Klinik Duisburg-West, Duisburg, Germany
🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany

and more 25 locations

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Phase 2

Recruiting

Conditions: Acute Biphenotypic Leukemia
Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Blasts 10 Percent or More of Peripheral Blood White Cells
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Gilteritinib
Drug: Idarubicin
Other: Laboratory Biomarker Analysis
Drug: Midostaurin
Drug: Venetoclax

First Posted Date: 2014-04-16

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 508

Registration Number: NCT02115295

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: Guadecitabine
Drug: Cladribine
Drug: Idarubicin

First Posted Date: 2014-03-26

Last Posted Date: 2024-08-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT02096055

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Acute Biphenotypic Leukemia
Previously Treated Myelodysplastic Syndrome
de Novo Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Mitoxantrone Hydrochloride

First Posted Date: 2014-01-24

Last Posted Date: 2020-01-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 199

Registration Number: NCT02044796

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis

Phase 2

Conditions: Systemic Mastocytosis

Interventions: Drug: Cladribine and pegylated interpheron alpha-2a

First Posted Date: 2012-05-21

Last Posted Date: 2016-08-29

Lead Sponsor: Hospital Virgen de la Salud

Target Recruit Count: 10

Registration Number: NCT01602939

Locations: 🇪🇸
Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Spain

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Decitabine

First Posted Date: 2012-01-24

Last Posted Date: 2025-01-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 160

Registration Number: NCT01515527

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Evaluation of Efficacy and Tolerance of Cladribine in Symptomatic Pulmonary Langerhans Cell Histiocytosis

Phase 2

Conditions: Langerhans Cell Histiocytosis of Lung

Interventions: Drug: Cladribine

First Posted Date: 2011-11-17

Last Posted Date: 2021-02-18

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 10

Registration Number: NCT01473797

Locations: 🇫🇷
Saint Louis hospital, Paris, France

R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Phase 2

Terminated

Conditions: Chronic Lymphocytic Leukaemia
Small Lymphocytic Lymphoma

Interventions: Drug: Rituximab
Drug: Cladribine

First Posted Date: 2011-10-05

Last Posted Date: 2018-01-31

Lead Sponsor: European Institute of Oncology

Target Recruit Count: 25

Registration Number: NCT01446900

Locations: 🇮🇹
European Institute of Oncology, Milan, Italy

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

Phase 1

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Rituximab
Drug: bortezomib
Drug: Cladribine

First Posted Date: 2011-09-23

Last Posted Date: 2017-08-07

Lead Sponsor: Milton S. Hershey Medical Center

Target Recruit Count: 13

Registration Number: NCT01439750

Locations: 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy